No Data
No Data
Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth?
Express News | Xilio Therapeutics Inc - Increased Size of Board to Nine Directors
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to Its Board of Directors
Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company's board of directors.
Xilio Therapeutics | 10-Q: Quarterly report
Express News | Xilio Therapeutics' Q1 Cash And Cash Equivalents Of $34M, $30M Upfront Payment Received In April 2024 Under Gilead Agreement And Approximately $14.6M In Gross Proceeds From Private Placement In April 2024 Are Expected To Provide Cash Runway Into Q2 2025
Express News | Xilio Therapeutics Q1 2024 GAAP EPS $(0.62) Compared To $(0.83) A Year Ago
No Data